Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

High efficacy of azacitidine combined with lenalidomide in TP53 mutation-positive and other high-risk myelodysplastic neoplasms

Xin Yan, Chunhua Song, Zheng Ge Nov 03, 2025 pp. 2082-2082 10.1182/blood-2025-2082

Abstract Background Myelodysplastic neoplasms (MDS) are heterogeneous clonal hematopoietic neoplasms, and TP53 mutations were regarded as ad...

Real-world outcomes in older adults with triple-class exposed multiple myeloma

Surbhi Sidana, Devender Dhanda, Sophie Hello et al. Nov 03, 2025 pp. 6368-6368 10.1182/blood-2025-6368

Abstract Introduction: Triple-class exposed (TCEx) multiple myeloma (MM) patients—those previously treated with an immunomodulatory agent (I...

Epidemiological trends in leukemia and heart failure-associated mortality: A CDC wonder database analysis

Hafsa Shahid, Ahmad Qaisar, Prachi Dawer et al. Nov 03, 2025 pp. 2824-2824 10.1182/blood-2025-2824

Abstract Background Leukemia and heart failure (HF) are individually associated with high morbidity and mortality. However, the intersection...

Single center updated analysis of patients with Relapsed/Refractory peripheral T-cell lymphoma treated with linperlisib.

Ranjit Nair, Sandra Lopez, Anita Aickareth et al. Nov 03, 2025 pp. 5432-5432 10.1182/blood-2025-5432

Abstract Peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) are aggressive malignancies with limited effective treatment...

HIV-1–Infected SCD patients exhibit milder sickle cell disease and suppressed antiviral innate immune responses

Namita Kumari, Marina Jerebtsova, Seyed Mehdi Nouraie et al. Nov 03, 2025 pp. 6486-6486 10.1182/blood-2025-6486

Abstract Sickle cell disease (SCD) is an inherited hemoglobinopathy characterized by chronic hemolytic anemia and complex pathology. SCD pat...

Imatinib in chronic myeloid leukemia: A comparative assessment of patients in pivotal clinical trials and real-world settings

Marisol Miranda, Josh Wilson, Yazmin Reategui Almonacid et al. Nov 03, 2025 pp. 8185-8185 10.1182/blood-2025-8185

Abstract Introduction: Several tyrosine kinase inhibitors (TKIs) are now available for the management of patients with chronic myeloid leuke...

Oxygen dependency as a critical regulatory axis affecting hematopoietic stem and progenitor cell function

James Ropa, Sarah Gutch, Lindsay Wathen et al. Nov 03, 2025 pp. 4964-4964 10.1182/blood-2025-4964

Abstract Hematopoietic stem (HSCs) and progenitor cells (HPCs) are responsible for lifelong replenishment of blood and immune cells and are...

Real-world measurable residual disease (MRD) testing patterns and associated outcomes in patients with Philadelphia-negative B-cell acute lymphoblastic leukemia

Anthony Proli, Jason Sharpe, Jingru Wang et al. Nov 03, 2025 pp. 4484-4484 10.1182/blood-2025-4484

Abstract Background:Measurableresidual disease (MRD) is an established prognostic biomarker in B-cell acute lymphoblastic leukemia (B-ALL) w...

Phase 2 trial of encorafenib plus binimetinib for patients with BRAF V600 mutated relapsed/refractory hairy cell leukemia

Robert Kreitman, Hao-Wei Wang, Dana Delgado Colon et al. Nov 03, 2025 pp. 5683-5683 10.1182/blood-2025-5683

Abstract Background: Hairy cell leukemia (HCL) is an indolent B-cell leukemia characterized by durable complete remissions to purine analogs...

Improved survival in Philadelphia Chromosome–Positive acute lymphoblastic leukemia with pre-transplant second- and third-generation TKIs and post-transplant prophylactic maintenance: A study from the EBMT ALWP

Iman Abou Dalle, Jacques-Emmanuel Galimard, Mohamed Houhou et al. Nov 03, 2025 pp. 6290-6290 10.1182/blood-2025-6290

Abstract Background: The use of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with Philadelphia chromosome-positi...

A machine learning approach identifies a transcriptomic signature predicting treatment-free remission in chronic myeloid leukemia

Vincent Alcazer, Stéphanie Dulucq, Isabelle Mosnier et al. Nov 03, 2025 pp. 76-76 10.1182/blood-2025-76

Abstract Introduction Treatment-free remission (TFR) is currently the ultimate goal for patients with chronic myeloid leukemia (CML). Howeve...

Low-intensity focused ultrasound with microbubbles enhances CD20 monoclonal antibody delivery across the blood-brain barrier in primary central nervous system lymphoma

Juan Huang, Jiawen Huang, Zhe Wu Nov 03, 2025 pp. 1793-1793 10.1182/blood-2025-1793

Abstract Abstract Objective: The objective of this study is to utilize low-intensity focused ultrasound (LIFU) in conjun...

Avoidance of ATG improves outcomes in double-cord blood transplantation for hematological malignancies

Leland Metheny, Tao Wang, Esteban Arrieta-Bolanos et al. Nov 03, 2025 pp. 2436-2436 10.1182/blood-2025-2436

Abstract Background Umbilical cord blood transplantation (CBT) is an alternative source of hematopoietic stem cells providing access to cura...

Burnout in sickle cell disease-focused hematology-oncology trained providers: A national cross-sectional study

Valentina Restrepo, Jennifer Afranie-Sakyi, Bria Carrithers et al. Nov 03, 2025 pp. 831-831 10.1182/blood-2025-831

Abstract Introduction: Burnout is defined by emotional exhaustion, depersonalization, and reduced personal accomplishment. It affects roughl...

Antiphospholipid antibodies (Anti-β2GPI/B2GPI) prime neutrophil NLRP3 inflammasome activation via TLR2/4 signaling

Asha Thomas, Devashis Mukherjee, Minghai Shao et al. Nov 03, 2025 pp. 191-191 10.1182/blood-2025-191

Abstract Background: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies...

XS003, an amorphous re-formulation of nilotinib, demonstrates improved dose linearity and minimal food effect, reducing the risk of QT-prolongation at fed conditions

Mikael von Euler, Charlotta Liljebris, Magnus Brisander et al. Nov 03, 2025 pp. 5547-5547 10.1182/blood-2025-5547

Abstract Background: Crystalline formulated nilotinib (Tasigna®) is an established tyrosine kinase inhibitor benefiting patients with chroni...

Evaluation of the maternal-fetal transfer of liposomal daunorubicin and cytarabine in an ex vivo human placenta perfusion model to inform Acute Myeloid Leukemia therapy

Sara Taveras Alam, Natalie Rafaeli, Adan Rios et al. Nov 03, 2025 pp. 6794-6794 10.1182/blood-2025-6794

Abstract Background & significance: Acute myeloid leukemia (AML) in pregnancy poses a therapeutic challenge and necessitates multidiscip...

Trials in progress: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation

Catherine Lai, Kimberley Doucette, Susan Mckay et al. Nov 03, 2025 pp. 8255-8255 10.1182/blood-2025-8255

Abstract Acute myeloid leukemia (AML) patients have a high risk of relapse. In patients ineligible for allogenic hematopoietic stem cell tra...

External validation of the early-stage classic Hodgkin lymphoma (cHL) international prognostication index (E-HIPI) in the german Hodgkin study group (GHSG) unfavorable clinical trials

Angie Mae Rodday, Dennis Eichenauer, Janina Jablonski et al. Nov 03, 2025 pp. 1845-1845 10.1182/blood-2025-1845

Abstract Background: Although progression-free survival (PFS) in early-stage (ES) classic Hodgkin Lymphoma (cHL) is high, there remains a su...

XPO1 inhibition by selinexor blocks nucleo-cytoplasmic trafficking of multiple members of the NF-kb family in MPN cell lines and primary myelofibrosis cells

Anthony Pomicter, Kristin Starr, Yurong Ouyang et al. Nov 03, 2025 pp. 7275-7275 10.1182/blood-2025-7275

Abstract Introduction: Selinexor, a first-in-class oral selective XPO1 inhibitor, in combination with ruxolitinib in JAK inhibitor-naïve pat...

Challenges in comparing outcomes of frontline clinical trials for diffuse large B-cell lymphoma patients selected based on the international prognostic index: A real-world analysis from the danish lymphoma registry

Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric et al. Nov 03, 2025 pp. 896-896 10.1182/blood-2025-896

Abstract Background: The International Prognostic Index (IPI) has been utilized in various frontline clinical trials to identify trial-eligi...

Characterization and risk factors of transplantation-associated thrombotic microangiopathy (TA-TMA): Increased incidence associated to post-transplant cyclophosphamide (PTCy) prophylaxis.

Monica Cabrero, Diego Clavo Martin, Carmen Rodríguez et al. Nov 03, 2025 pp. 7729-7729 10.1182/blood-2025-7729

Abstract Introduction Transplant-associated thrombotic microangiopathy (TA-TMA) is a potentially severe post-transplant...

Single-cell insights into acute myeloid leukemia treated with venetoclax-based therapy

Prajwal Dhakal, Michael Chimenti, Benjamin Darbro et al. Nov 03, 2025 pp. 1499-1499 10.1182/blood-2025-1499

Abstract Introduction Acute myeloid leukemia(AML) is a heterogeneous malignancy marked by impaired myeloid differentiation and resistance to...

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner et al. Nov 03, 2025 pp. 3852-3852 10.1182/blood-2025-3852

Abstract Introduction: Standardized reporting of clinical trials results for MDS is essential to improve clinical interpretation and cross-st...

Clinical impact of predicted indirectly recognizable HLA epitopes (PIRCHE) in single unit cord blood transplantation using tacrolimus and methotrexate for graft-versus-host disease prophylaxis

Tomoki Naito, Hiroko Otsuji, Tomohiro Khomoto et al. Nov 03, 2025 pp. 4290-4290 10.1182/blood-2025-4290

Abstract Background: The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) algorithm estimates the potential for indirect recognition...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page